[go: up one dir, main page]

UA83152C2 - Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид - Google Patents

Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид

Info

Publication number
UA83152C2
UA83152C2 UAA200704303A UAA200704303A UA83152C2 UA 83152 C2 UA83152 C2 UA 83152C2 UA A200704303 A UAA200704303 A UA A200704303A UA A200704303 A UAA200704303 A UA A200704303A UA 83152 C2 UA83152 C2 UA 83152C2
Authority
UA
Ukraine
Prior art keywords
donepezil hydrochloride
pharmaceutical composition
solid pharmaceutical
relates
composition
Prior art date
Application number
UAA200704303A
Other languages
English (en)
Ukrainian (uk)
Inventor
Міха Врбінк
Берта Котар-Йордан
Рок Зупет
Матей Смрколй
Original Assignee
Крка, Товарна Здравіл, Д.Д., Ново Мєсто
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35464350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA83152(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Крка, Товарна Здравіл, Д.Д., Ново Мєсто filed Critical Крка, Товарна Здравіл, Д.Д., Ново Мєсто
Publication of UA83152C2 publication Critical patent/UA83152C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

Изобретение относится к фармацевтике, в частности к твердой фармацевтической композиции, содержащей донепезила гидрохлорид в форме гидрата и наполнители, а также к способу ее получения. Донепезил гидрохлорид сохраняет свою полиморфную форму и, таким образом, является высокостойким к превращению в другие полиморфные формы.
UAA200704303A 2004-10-19 2005-10-19 Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид UA83152C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004051055 2004-10-19

Publications (1)

Publication Number Publication Date
UA83152C2 true UA83152C2 (ru) 2008-06-10

Family

ID=35464350

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200704303A UA83152C2 (ru) 2004-10-19 2005-10-19 Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид

Country Status (19)

Country Link
US (3) US20090130205A9 (ru)
EP (3) EP2039349A1 (ru)
JP (1) JP2008517022A (ru)
AT (1) ATE415148T1 (ru)
CA (1) CA2584547C (ru)
CY (1) CY1109956T1 (ru)
DE (1) DE602005011326D1 (ru)
DK (1) DK1811957T3 (ru)
EA (1) EA012220B1 (ru)
ES (1) ES2317313T3 (ru)
HR (1) HRP20090104T3 (ru)
NO (1) NO20072494L (ru)
PL (1) PL1811957T3 (ru)
PT (1) PT1811957E (ru)
RS (1) RS51271B (ru)
SI (1) SI1811957T1 (ru)
UA (1) UA83152C2 (ru)
WO (1) WO2006045512A1 (ru)
ZA (1) ZA200704023B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515803D0 (en) * 2005-07-30 2005-09-07 Pliva Hrvatska D O O Intermediate compounds
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
US20070264330A1 (en) * 2006-05-15 2007-11-15 Bo Ragnar-Tolf Pharmaceutical formulations of pimavanserin
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
WO2008092011A2 (en) * 2007-01-24 2008-07-31 Cook Incorporated Biofilm-inhibiting medical products
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
DE102007037932A1 (de) 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
DE102010010998A1 (de) * 2010-03-10 2011-09-15 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
SG190406A1 (en) * 2010-11-30 2013-06-28 Wista Lab Ltd Formulations comprising methylthioninium chloride
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
US20150216849A1 (en) 2014-02-04 2015-08-06 Forest Laboratories Holdings Ltd. Donepezil compositions and methods of treating alzheimers disease
CN114272219B (zh) * 2021-12-30 2023-11-10 江苏豪森药业集团有限公司 一种盐酸多奈哌齐片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
CA2252806C (en) * 1996-06-07 2005-11-22 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
US6390821B1 (en) * 1997-02-07 2002-05-21 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
WO1999042599A1 (en) * 1998-02-19 1999-08-26 Sapporo Breweries Ltd. Isolated and purified nucleic acids comprising a gene specifically expressed in hop glands
EP1086706B1 (en) 1999-03-31 2003-11-26 Eisai Co., Ltd. Stabilized compositions containing nootropic drugs
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1260215T3 (da) * 2000-03-01 2009-11-09 Eisai R&D Man Co Ltd Hurtig disintegrerende tablet indeholdende polyvinylalkohol
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192180B (ru) * 2001-09-28 2004-03-06 Ranbaxy Lab
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
MXPA05005528A (es) * 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Also Published As

Publication number Publication date
CY1109956T1 (el) 2014-09-10
PL1811957T3 (pl) 2009-05-29
ZA200704023B (en) 2008-04-30
WO2006045512A1 (en) 2006-05-04
HRP20090104T3 (en) 2009-03-31
US20090130205A9 (en) 2009-05-21
SI1811957T1 (sl) 2009-04-30
ATE415148T1 (de) 2008-12-15
JP2008517022A (ja) 2008-05-22
EP2283811A1 (en) 2011-02-16
CA2584547A1 (en) 2006-05-04
EA012220B1 (ru) 2009-08-28
NO20072494L (no) 2007-07-02
US20100317694A1 (en) 2010-12-16
DE602005011326D1 (de) 2009-01-08
EP1811957B1 (en) 2008-11-26
ES2317313T3 (es) 2009-04-16
RS51271B (sr) 2010-12-31
EA200700673A1 (ru) 2007-10-26
PT1811957E (pt) 2009-01-27
US20120283291A1 (en) 2012-11-08
EP1811957A1 (en) 2007-08-01
CA2584547C (en) 2014-07-08
DK1811957T3 (da) 2009-03-30
EP2039349A1 (en) 2009-03-25
US20080063705A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
UA83152C2 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
TWI315306B (en) Bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
HK1096387A1 (en) ß-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
SI1695709T1 (sl) Gama-d kristalna oblika hidroklorida ivabradina, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
ZA200608404B (en) Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
ZA200608403B (en) Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
PT2210872T (pt) Nova forma cristalina iii de agomelatina, processo para a sua preparação e composições farmacêuticas que a contêm
PL1752443T3 (pl) Nowa postać krystaliczna V agomelatyny, sposób jej wytwarzania i kompozycje farmaceutyczne, które ją zawierają
UA90130C2 (ru) Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе
IL181827A0 (en) Donepezil salts suitable for the preparation of pharmaceutical compositions
WO2007073888A3 (de) Pharmazeutische zusammensetzung enthaltend donepezilhydrochlorid, tablette hieraus und verfahren zu deren herstellung
ZA200805477B (en) Pharmaceutical composition containing chenopodium ambrosioides extract and its preparing process and application
GB2456096A (en) Crystalline form of benzothiophene compound and process for preparation thereof
PL1783105T3 (pl) Kompozycja zaprawowa, sposób jej wytwarzania i jej zastosowanie
IL189177A0 (en) Process for producing carcosporamide and pharmaceutical compositions containing cercosporamide
PL1758569T3 (pl) Sole guanylohydrazonowe, kompozycje, sposoby ich wytwarzania i stosowania
AU2006200854B2 (en) bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AU2006200857B2 (en) y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it